OncoC4 Initiates First Phase 1/2 Clinical Trial for Alzheimer's Disease Therapy ONC-841
OncoC4 Inc., a biopharmaceutical company based in Rockville, Maryland, has made a significant advancement in the fight against Alzheimer's disease. On April 9, 2026, the company announced that it has successfully dosed the first participant in a Phase 1/2 clinical trial for its investigational drug, ONC-841. This milestone follows the recent clearance of their Investigational New Drug (IND) application by the National Medical Product Administration (NMPA).
ONC-841 is notable for being the first and only clinical-stage anti-SIGLEC 10 antibody, developed to target a novel mechanism in the treatment of Alzheimer's disease. Initially, it was being tested in a Phase 2 trial focused on patients with solid tumors, where it displayed promising results. Recent preclinical findings have highlighted ONC-841's potential in enhancing the function of microglia, crucial cells in the brain responsible for clearing harmful protein aggregates that contribute to neurodegenerative diseases.
The accelerated approval for this Alzheimer's trial leveraged the safety data collected during the oncology trials, facilitating a quicker entry into testing for neurodegenerative conditions. The first participant was dosed at Xuanwu Hospital of Capital Medical University in China, a recognized center for Alzheimer's research.
Dr. Yang Liu, the CEO and Chief Scientific Officer of OncoC4, expressed enthusiasm about extending their research from oncology to Alzheimer’s, emphasizing the collaboration with Xuanwu Hospital. He stated, "This transition exemplifies OncoC4's robust research capabilities and the invaluable infrastructure provided by Xuanwu Hospital as a leading authority in Alzheimer's research."
Professor Yi Tang, one of the Principal Investigators for this trial and the Executive Vice President at Xuanwu Hospital, reiterated the excitement surrounding the study. He remarked, "We are thrilled to explore the potential of targeting SIGLEC 10, a novel checkpoint in the development of Alzheimer's disease, and are hopeful this will lead to meaningful benefits for patients."
OncoC4's strategic vision extends beyond Alzheimer's, as the company continues to innovate with other pipeline candidates, including AI-081, a bispecific antibody that targets PD-1 and VEGF. The ongoing research reflects OncoC4's commitment to addressing various diseases within the fields of oncology and immunology. The engagement of high-level academic institutions like Xuanwu Hospital underscores the collaborative nature of modern biopharmaceutical development, and together, they aim to usher in new treatment paradigms for some of the most challenging diseases today.
This Phase 1/2 trial has been registered under the clinical trial number CTR20260866, marking a pivotal step in OncoC4's journey to expand its portfolio into neurodegenerative disorders. As this trial progresses, the results could provide new insights into the treatment options available for Alzheimer's disease, potentially bringing hope to countless individuals and families affected by this devastating disorder. For more detailed information about OncoC4 and their innovative research, you can visit their website at www.oncoc4.com.
ONC-841 is notable for being the first and only clinical-stage anti-SIGLEC 10 antibody, developed to target a novel mechanism in the treatment of Alzheimer's disease. Initially, it was being tested in a Phase 2 trial focused on patients with solid tumors, where it displayed promising results. Recent preclinical findings have highlighted ONC-841's potential in enhancing the function of microglia, crucial cells in the brain responsible for clearing harmful protein aggregates that contribute to neurodegenerative diseases.
The accelerated approval for this Alzheimer's trial leveraged the safety data collected during the oncology trials, facilitating a quicker entry into testing for neurodegenerative conditions. The first participant was dosed at Xuanwu Hospital of Capital Medical University in China, a recognized center for Alzheimer's research.
Dr. Yang Liu, the CEO and Chief Scientific Officer of OncoC4, expressed enthusiasm about extending their research from oncology to Alzheimer’s, emphasizing the collaboration with Xuanwu Hospital. He stated, "This transition exemplifies OncoC4's robust research capabilities and the invaluable infrastructure provided by Xuanwu Hospital as a leading authority in Alzheimer's research."
Professor Yi Tang, one of the Principal Investigators for this trial and the Executive Vice President at Xuanwu Hospital, reiterated the excitement surrounding the study. He remarked, "We are thrilled to explore the potential of targeting SIGLEC 10, a novel checkpoint in the development of Alzheimer's disease, and are hopeful this will lead to meaningful benefits for patients."
OncoC4's strategic vision extends beyond Alzheimer's, as the company continues to innovate with other pipeline candidates, including AI-081, a bispecific antibody that targets PD-1 and VEGF. The ongoing research reflects OncoC4's commitment to addressing various diseases within the fields of oncology and immunology. The engagement of high-level academic institutions like Xuanwu Hospital underscores the collaborative nature of modern biopharmaceutical development, and together, they aim to usher in new treatment paradigms for some of the most challenging diseases today.
This Phase 1/2 trial has been registered under the clinical trial number CTR20260866, marking a pivotal step in OncoC4's journey to expand its portfolio into neurodegenerative disorders. As this trial progresses, the results could provide new insights into the treatment options available for Alzheimer's disease, potentially bringing hope to countless individuals and families affected by this devastating disorder. For more detailed information about OncoC4 and their innovative research, you can visit their website at www.oncoc4.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.